Yan Wang1, Yue-Chang Yang2, Dan-Mei Lan3, Hui -Juan Wu3, Zhong-Xin Zhao4. 1. Department of Neurology, No. 88 Hospital of PLA, Taian, Shandong, China. 2. Department of Neurology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai, 200003, China. 3. Sleep Center, Changzheng Hospital, Second Military Medical University, Shanghai, China. 4. Department of Neurology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai, 200003, China. zhaozx2014@126.com.
Abstract
PURPOSE: Sleep disturbance is common in Parkinson's disease (PD) and negatively impacts quality of life. There is little data on how dopamine agonists influence nocturnal sleep in PD, particularly in sleep laboratory data to measure sleep parameters and their changes objectively. The goal of this open-label study was to objectively evaluate the effect of rotigotine on sleep in PD patients by video-polysomnographic methods. METHODS: A total of 25 PD patients with complaints of nocturnal sleep impairment were enrolled. The sleep quality before and after stable rotigotine therapy was evaluated subjectively through questionnaire assessments and objectively measured by video-polysomnographic methods. The Parkinsonism, depression, anxiety, and quality of life of PD patients were also evaluated through questionnaire assessments. RESULTS: At the end of rotigotine treatment, the PD daytime functioning, motor performance, depression, subjective quality of sleep, and the quality of life improved. Video-polysomnographic analysis showed that the sleep efficiency and stage N1% were increased, while the sleep latency, wake after sleep onset, and the periodic leg movements in sleep index were decreased after rotigotine treatment. CONCLUSIONS: Video-polysomnographic analysis confirmed the subjective improvement of sleep after rotigotine treatment. This observation suggests that in PD rotigotine is a treatment option for patients complaining from sleep disturbances.
PURPOSE: Sleep disturbance is common in Parkinson's disease (PD) and negatively impacts quality of life. There is little data on how dopamine agonists influence nocturnal sleep in PD, particularly in sleep laboratory data to measure sleep parameters and their changes objectively. The goal of this open-label study was to objectively evaluate the effect of rotigotine on sleep in PDpatients by video-polysomnographic methods. METHODS: A total of 25 PDpatients with complaints of nocturnal sleep impairment were enrolled. The sleep quality before and after stable rotigotine therapy was evaluated subjectively through questionnaire assessments and objectively measured by video-polysomnographic methods. The Parkinsonism, depression, anxiety, and quality of life of PDpatients were also evaluated through questionnaire assessments. RESULTS: At the end of rotigotine treatment, the PD daytime functioning, motor performance, depression, subjective quality of sleep, and the quality of life improved. Video-polysomnographic analysis showed that the sleep efficiency and stage N1% were increased, while the sleep latency, wake after sleep onset, and the periodic leg movements in sleep index were decreased after rotigotine treatment. CONCLUSIONS: Video-polysomnographic analysis confirmed the subjective improvement of sleep after rotigotine treatment. This observation suggests that in PD rotigotine is a treatment option for patients complaining from sleep disturbances.
Authors: Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira Journal: Mov Disord Date: 2007-10-15 Impact factor: 10.338
Authors: Jacques Montplaisir; Jean-Francois Gagnon; Maria Livia Fantini; Ronald B Postuma; Yves Dauvilliers; Alex Desautels; Sylvie Rompré; Jean Paquet Journal: Mov Disord Date: 2010-10-15 Impact factor: 10.338
Authors: K Ray Chaudhuri; P Martinez-Martin; K A Rolfe; J Cooper; C B Rockett; L Giorgi; W G Ondo Journal: Eur J Neurol Date: 2011-06-23 Impact factor: 6.089
Authors: Maartje Louter; Willemijn C C A Aarden; Joy Lion; Bastiaan R Bloem; Sebastiaan Overeem Journal: J Neurol Date: 2012-04-26 Impact factor: 4.849
Authors: Claudia Trenkwalder; Bryan Kies; Monika Rudzinska; Jennifer Fine; Janos Nikl; Krystyna Honczarenko; Peter Dioszeghy; Dennis Hill; Tim Anderson; Vilho Myllyla; Jan Kassubek; Malcolm Steiger; Marco Zucconi; Eduardo Tolosa; Werner Poewe; Erwin Surmann; John Whitesides; Babak Boroojerdi; Kallol Ray Chaudhuri Journal: Mov Disord Date: 2010-11-18 Impact factor: 10.338
Authors: Hind A Beydoun; Jiu-Chiuan Chen; Nazmus Saquib; Michelle J Naughton; May A Beydoun; Aladdin H Shadyab; Lauren Hale; Alan B Zonderman Journal: J Affect Disord Date: 2022-06-22 Impact factor: 6.533
Authors: Hind A Beydoun; Sharmin Hossain; Shuyan Huang; May A Beydoun; Brook T Alemu; Shaker M Eid; Alan B Zonderman Journal: Psychosom Med Date: 2021-06-01 Impact factor: 3.864
Authors: Miguel Rosa-Grilo; Mubasher A Qamar; Raquel N Taddei; Javier Pagonabarraga; Jaime Kulisevsky; Anna Sauerbier; K Ray Chaudhuri Journal: NPJ Parkinsons Dis Date: 2017-09-05